Table 2: Immunohistochemical evaluation of protein expression of the selected target genes in various tumor categories.

GeneChrStatus in RKOPilot study, % loss in MSS sporadic cancers, ( value)% loss in MSI sporadic cancers, ( value)% loss in sporadic adenoma, ( value)% loss in Lynch-colon cancers, ( value)% loss in FCCX, ( value)

1IFI161q22UpregulatedLoss 43% not correlated with β-catenin localizationNDNDNDNDND

2RGS41q23.3UpregulatedRGS4 nuclear localization in 56% of tumors correlated with nuclear β-catenin58% cytoplasmic (NS) 50% cytoplasmic (NS)NDNDND

3MCTP15q15Upregulated50% membranous, 50% cytoplasmic, not correlated with β-catenin localizationNDNDNDNDND

4DGKI7q32.3–q33UpregulatedLoss correlated with localization55% (0.0001)69% (0.0001)30% (NS)63% (0.0001)50% (0.002)

5OBCAM/OPCML11q25UpregulatedLoss in 55% but not correlated with β-catenin localization60% (NS)50% (NS)70% (NS)68% (NS)15% (NS)

6GLIPR112q21.2UpregulatedLoss correlated with localization33% (0.005)27% (0.005)27% (0.001)44% (0.001)40% (0.035)

value is for loss of the expression versus β-catenin subcellular localization.
Highlighted in bold are GLIPR1 and DGKI findings which correlated with β-catenin status in a pattern similar to that observed in the microarray.
ND, not done; NS, not significant.